Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Success For Mirati As EMA Backs Krazati For EU Approval After Initial Rejection

13 Nov 2023

• By Eliza Slawther

• Source: Shutterstock

Related Content

EMA Says Yes To GSK’s Omjjara, UCB’s Rystiggo and Novartis’ Spexotras

10 Nov 2023

Mirati To Challenge EMA’s Rejection Of US-Approved Krazati

21 Jul 2023

Related Companies

Mirati Therapeutics, Inc.

Amgen, Inc.

Additional Topics

Europe EU Approvals Drug Review Market Access Regulation BioPharmaceutical Cancer

More from Europe

More from Geography

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.